Accelerating Approval Pathway for Phase III Ovarian Cancer Trial

This case study outlines the management of a global phase III confirmatory trial by Worldwide Clinical Trials for a small biotech developing a combination therapy for a rare form of ovarian cancer. The study was critical for an Accelerated Approval application to the U.S. FDA, necessitating rapid startup and recruitment due to the rare nature of the indication. The anticipated enrollment rate posed significant challenges, requiring over 100 sites globally to meet the two-year enrollment goal. The case study details the strategies implemented by Worldwide to address these challenges, including data-driven site selection and collaboration with regional cooperative groups. The urgency was heightened by shifting FDA expectations regarding trial timelines, prompting Worldwide to mobilize a seasoned study team and enhance patient awareness efforts. Ultimately, the trial initiation and enrollment milestones were met successfully, supporting the NDA submission and the hope for FDA approval of the first treatment specifically for this indication.